Kodiak Sciences Inc.

NASDAQ: KOD · Healthcare · Biotechnology

PublicHQ Palo Alto, CA · Santa ClaraCIK 0001468748Reports USD

#1 of 1,417 Healthcare companies by revenue

EA Score

——

FH 35DQ —GM —SS 64

v0.1 · 35/100 weight · pillars only

↑ market scale, workforce scale · ↓ Piotroski F, filing timeliness

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$230.0M

Employees

124

as of 2026-08-09

Market cap

$2.8B

as of 2026-08-09

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$230.0M-$230.0M2025

Operating income-$234.4M-$234.4M2025

Total assets$351.5M$351.5M2025

Liabilities$194.2M$194.2M2025

Equity$157.4M$157.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Kodiak Sciences Inc.’s financial profile?

Kodiak Sciences Inc. earned -$230.0M in FY2025 net income.

Peers · Healthcare

MBX Biosciences, Inc. Common Stock——Structure Therapeutics Inc.——Disc Medicine, Inc.——Trevi Therapeutics, Inc.——Mineralys Therapeutics, Inc.——Vera Therapeutics, Inc.——

Neighbors

Santa Clara →

NVIDIA Corporation$215.9B90A Apple Inc.$416.2B84B+Alphabet Inc.$402.8B81B+Broadcom Inc.$63.9B76B+Advanced Micro Devices, Inc.$34.6B78B+Cisco Systems, Inc.$56.7B85A

Key facts

CEOVictor Perlroth

SectorHealthcare

IndustryBiotechnology

HeadquartersPalo Alto, CA

ExchangeNASDAQ: KOD

Employees124

IPO date2018-10-04

Latest filings

10-Q2026-08-13 8-K2026-08-13 8-K2026-06-04 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-22 8-K2026-03-31 10-K2026-03-31

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.